-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Amyloid Consults Do Not Have to be Vexing

Program: Education Program
Session: How Do We Enhance Results in Rare Hematologic Malignancies?
Sunday, December 10, 2023, 9:30 AM-10:45 AM

Anita D'Souza, MD, MS

Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

Disclosures: D'Souza: Imbrium, Pfizer, Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Janssen, Prothena: Consultancy; Abbvie, Sanofi, Takeda, TeneoBio, Caelum, Prothena: Research Funding.

See more of: How Do We Enhance Results in Rare Hematologic Malignancies?
See more of: Education Program
<< Previous Presentation | Next Presentation